Mindset Pharma Begins Work with Leading R&D Contractor for Next-Generation Psychedelic Drugs

April 14, 2020

TORONTO, April 14, 2020 /CNW/ - Mindset Pharma ("Mindset"), a leading drug discovery business focused exclusively on novel and best in class psychedelics, announced today that preclinical work has begun on the novel psychedelics identified in Mindset's provisional patent applications filed earlier this year. Mindset has identified multiple novel compound structures that the Mindset scientific team believes will enable the development of pharmaceutically appropriate next-generation psychedelic drugs to treat a range of neuropsychiatric indications. The novel compounds identified by Mindset will enable drugs that combine medically desirable psychedelic effects with optimal pharmacological characteristics.


Initial compound synthesis and in-vitro screening are being provided to Mindset by a premier R&D service company supporting the life science industry. 


Mindset CEO, James Lanthier, said, "We are pleased to establish a service agreement, which continues to be fully operational through the COVID pandemic. Importantly, working with a leading R&D contractor will allow us to adhere to our timelines to select our first clinical candidate before the end of the year and will allow us to maintain our first-to-file advantage and remain ahead of the curve as the exciting medical psychedelic space continues to evolve."


Mindset continues to work on broadening the scope of their intellectual property assets. The Mindset scientific team are working on a series of additional patent applications for novel psychedelic analogs and related manufacturing processes.


About Mindset
Mindset Pharma is a drug discovery business, based in Toronto, Canada, focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.


SOURCE Mindset Pharma


For further information: Alex Krause, Alan Aldous Communications, (519) 835-8345, Alex@AlanAldous.com

Mindset

Sign-up for company updates

Copyright © 2019 - All Rights Reserved by Mindset Pharma Inc.